A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
Sponsor: Glaxo Wellcome
Listed as NCT00001994, this NA trial focuses on HIV Infections and Toxoplasmosis, Cerebral and remains completed. Sponsored by Glaxo Wellcome, it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Glaxo Wellcome
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Annandale, United States, Atlanta, United States, Baltimore, United States, Calgary, Canada, Durham, United States, Houston, United States, Los Angeles, United States, Memphis, United States, Montreal, Canada, New York, United States and 7 more location s